Table 3 Antimycobacterial susceptibility testing results for environmental isolates
Bacteria (no.) and antimicrobial agent | MIC (µg/ml) | No. (%) of isolates | ||||
|---|---|---|---|---|---|---|
Range | 50% | 90% | Susceptible | Intermediate | Resistant | |
M. aurum (n = 28) | ||||||
Clarithromycin | 0.5—≥ 16 | 0.5 | ≥ 8 | 15 (53.8%) | 2 (7.1%) | 9 (39.1%) |
Tobramycin | 2 – ≤ 2–4 | 2 | 4 | 28 (100.0%) | 0 (0.0%) | 0 (0.0%) |
Amikacin | ≤ 1– ≤ 1–2 | ≤ 1 | 2 | 21 (75.0%) | 0 (0.0%) | 7 (25.2%) |
Doxycycline | ≤ 0.25 – ≤ 0.25–0.50 | 0.25 | 0.50 | 17 (60.7%) | 1 (3.6%) | 10 (35.7%) |
Cefoxitin | ≤ 4 – ≤ 2–8 | 4 | 8 | 8 (28.6%) | 4 (14.3%) | 16 (57.1%) |
Trimethoprim/sulfamethoxazole | ≤ 0.25 – 4 | 0.25 | 4 | 25 (89.3%) | 1 (3.6%) | 2 (7.1%) |
Linezolid | ≤ 1– ≤ 2 | ≤ 1 | 1 | 27 (96.4%) | 0 (0.0%) | 1 (3.6%) |
Ciprofloxacin | ≤ 0.12– ≤ 0.5 | ≤ 0.12 | 0.25 | 15 (53.8%) | 1 (3.6%) | 12 (42.6%) |
Meropenem | ≤ 1– ≤ 2 | ≤ 1 | 1 | 20 (71.4%) | 0 (0.0%) | 8 (28.6%) |
Imipenem | ≤ 1– ≤ 2 | ≤ 1 | 1 | 15 (53.8%) | 1 (3.6%) | 12 (42.6%) |
Moxifloxacin | ≤ 0.25– ≤ 0.25 | 0.06 | ≤ 0.25 | 15 (53.8%) | 2 (7.1%) | 11 (39.1%) |
M. phocaicum (n = 20) | ||||||
Clarithromycin | ≤ 2—≥ 8 | ≤ 2 | ≥ 8 | 18 (90.0%) | 0 (0.0%) | 0 (10.0%) |
Tobramycin | ≤ 4–8 – ≥ 32 | 4 | 8 | 9 (45.0%) | 1 (5.0%) | 10 (50.0%) |
Amikacin | ≤ 16–32 – ≥ 64 | 16 | 32 | 19 (95.0%) | 0 (0.0%) | 1 (5.0%) |
Doxycycline | ≤ 1–8 – ≥ 16 | 4 | 16 | 8 (40.0%) | 2 (10.0%) | 10 (50.0%) |
Cefoxitin | ≤ 16–32 – ≥ 128 | 16 | 64 | 17 (85.0%) | 0 (0.0%) | 3 (25.0%) |
Trimethoprim/sulfamethoxazole | ≤ 1—≥ 4 | 1 | 4 | 19 (95.0%) | 0 (0.0%) | 1 (5.0%) |
Linezolid | ≤ 8–16 – ≥ 32 | 8 | 32 | 18 (90.0%) | 0 (0.0%) | 0 (10.0%) |
Ciprofloxacin | ≤ 1–2 – ≥ 4 | 1 | 4 | 3 (15.1%) | 1 (5.0%) | 16 (80.0%) |
Meropenem | ≤ 4 – 8 | 2 | 4 | 15 (75.0%) | 1 (5.0%) | 4 (20.0%) |
Imipenem | ≤ 4–8 – ≥ 16 | 4 | 8 | 17 (85.0%) | 0 (0.0%) | 3 (25.0%) |
Moxifloxacin | ≤ 1–2 – ≥ 4 | 1 | 4 | 19 (95.0%) | 0 (0.0%) | 1 (5.0%) |
M. mucogenicum (n = 16) | ||||||
Clarithromycin | ≤ 2–4—≥ 8 | 2 | 8 | 15 (93.8%) | 0 (0.0%) | 1 (6.2%) |
Tobramycin | ≤ 4–8 – ≥ 16 | 4 | 16 | 14 (87.5%) | 1 (6.2%) | 1 (6.2%) |
Amikacin | 0.5 –64 | 0.5 | 32 | 16 (100.0%) | 0 (0.0%) | 0 (0.0%) |
Doxycycline | 0.25 –32 | 0.25 | 16 | 11 (68.8%) | 1 (6.2%) | 4 (25.0%) |
Cefoxitin | ≤ 16–32 – ≥ 128 | 8 | 64 | 15 (93.8%) | 0 (0.0%) | 1 (6.2%) |
Trimethoprim/sulfamethoxazole | ≤ 1—4 | 1 | 4 | 15 (93.8%) | 1 (6.2%) | 0 (0.0%) |
Linezolid | 1–4 – 128 | 1 | 64 | 15 (93.8%) | 0 (0.0%) | 1 (6.2%) |
Ciprofloxacin | ≤ 1– ≥ 128 | 1 | 64 | 14 (87.5%) | 0 (0.0%) | 2 (12.5%) |
Meropenem | ≤ 4 – ≥ 16 | 4 | 8 | 12 (75.0%) | 0 (0.0%) | 4 (25.0%) |
Imipenem | ≤ 1 – ≥ 128 | 1 | 64 | 15 (93.8%) | 0 (0.0%) | 1 (6.2%) |
Moxifloxacin | ≤ 1–2 – ≥ 4 | 1 | 4 | 15 (93.8%) | 1 (6.2%) | 0 (0.0%) |
M. fortuitum (n = 12) | ||||||
Clarithromycin | 0.06–64 | 2 | 8 | 8 (66.7%) | 0 (0.0%) | 4 (33.3%) |
Tobramycin | 0.25–32 | 2 | 4 | 11 (91.7%) | 0 (0.0%) | 1 (8.3%) |
Amikacin | 0.125–128 | 1 | 8 | 11 (91.7%) | 0 (0.0%) | 1 (8.3%) |
Doxycycline | 0.25–128 | 8 | 32 | 2 (16.7%) | 0 (0.0%) | 10 (83.8%) |
Cefoxitin | 2–256 | 32 | 64 | 4 (33.3%) | 1 (8.3%) | 7 (58.4%) |
Trimethoprim/sulfamethoxazole | 1–32 | 2 | 8 | 11 (91.7%) | 1 (8.3%) | 0 (0.0%) |
Linezolid | 0.25–64 | 2 | 32 | 8 (66.7%) | 1 (8.3%) | 3 (25.0%) |
Ciprofloxacin | 0.06–16 | 0.25 | 8 | 5 (41.7%) | 1 (8.3%) | 6 (50.0%) |
Meropenem | 1–128 | 4 | 32 | 6 (50.0%) | 1 (8.3%) | 4 (33.3%) |
Imipenem | 0.06–64 | 1 | 8 | 5 (41.7%) | 1 (8.3%) | 6 (50.0%) |
Moxifloxacin | 0.06–64 | 0.125 | 16 | 7 (58.4%) | 0 (0.0%) | 5 (41.7%) |
M. kansasii (n = 18) | ||||||
Isoniazid | 0.25–16 | 2 | 4 | 18 (100.0%) | 0 (0.0%) | 0 (0.0%) |
Rifampicin | 0.125–16 | 2 | 8 | 5 (27.8%) | 1 (5.5%) | 12 (66.7%) |
Ethambutol | 0.25–64 | 2 | 4 | 18 (100.0%) | 0 (0.0%) | 0 (0.0%) |
Clarithromycin | 0.125–32 | 0.125 | 2 | 18 (100.0%) | 0 (0.0%) | 0 (0.0%) |
Moxifloxacin | 0.125–2 | 0.125 | 1 | 18 (100.0%) | 0 (0.0%) | 0 (0.0%) |
Linezolid | 0.125–2 | 0.125 | 1 | 18 (100.0%) | 0 (0.0%) | 0 (0.0%) |
Ciprofloxacin | 0.25–16 | 1 | 4 | 5 (22.2%) | 2 (11.1%) | 12 (66.7%) |
M. simiae (n = 18) | ||||||
Isoniazid | 16–128 | 32 | 64 | 0 (0.0%) | 0 (0.0%) | 18 (100.0%) |
Rifampicin | 0.5–128 | 4 | 64 | 0 (0.0%) | 0 (0.0%) | 18 (100.0%) |
Ethambutol | 4–64 | 8 | 32 | 0 (0.0%) | 0 (0.0%) | 18 (100.0%) |
Streptomycin | 2–64 | 16 | 32 | 0 (0.0%) | 0 (0.0%) | 18 (100.0%) |
Amikacin | 0.06–64 | 2 | 16 | 16 (89.0%) | 1 (5.5%) | 1 (5.5%) |
Ofloxacin | 0.25–64 | 4 | 32 | 17 (94.5%) | 1 (5.5%) | 0 (0.0%) |
Ciprofloxacin | 0.25–64 | 4 | 32 | 16 (89.0%) | 0 (0.0%) | 2 (11.0%) |
Trimethoprim/sulfamethoxazole | 16–512 | 32 | 256 | 0 (0.0%) | 0 (0.0%) | 18 (100.0%) |
Clarithromycin | 32–128 | 32 | 64 | 0 (0.0%) | 0 (0.0%) | 18 (100.0%) |